The European Patent Office Thursday invalidated and revoked Edwards Lifesciences’ EP2055266 Spenser patent, the basis for the Sapien transcatheter heart valve and source of an injunction against sales of Medtronic’s CoreValve system in Germany.
Medtronic lauded the ruling, saying it will ensure that European patients have access to aortic valve replacement therapy.
Edwards spokeswoman Sarah Huoh said the company will appeal the decision. She stressed that the decision has “no impact on Edwards’ ability to offer the Edwards SAPIEN XT or SAPIEN 3 transcatheter heart valves.”
Thursday’s ruling follows a preliminary ruling by the EPO in October and a November order by Germany’s Higher Regional Court in Karlsruhe to discontinue a lower court injunction against CoreValve. — Lena Freund
Subscribe to Devices & Diagnostics Letter for complete coverage of the medical devices industry. Click here for more information.